Short Operating History and Difficulty Forecasting Future Performance from Historical Results
First written in FY2019. 4 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 7 companies on the "Worse" side.
8 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「We are a company with a limited operating history, having been established in January 2000. We are also a specialized company focused on the so-called drug discovery sector. We plan to generate business revenue and secure profits in the future by launching anticancer drugs we develop, but we have not generated business revenue from product sales to date.」
The company continues to face the risk that future performance is difficult to predict based solely on past results, given the absence of product sales and its business characteristics, including its operating history and focus on drug discovery. - FY2022RestatedAnnual report
「We are a company with a limited operating history, having been established in January 2000. We are also a specialized company focused on the so-called drug discovery sector. We plan to generate business revenue and secure profits in the future by launching anticancer drugs we develop, but we have not generated business revenue from product sales to date.」
The company continues to face the risk that future performance is difficult to predict based solely on past results, given the absence of product sales and its business characteristics, including its operating history and focus on drug discovery. - FY2021RestatedAnnual report
「We are a company with a limited operating history, having been established in January 2000. We are also a specialized company focused on the so-called drug discovery sector. We plan to generate business revenue and secure profits in the future by launching anticancer drugs we develop, but we have not generated business revenue from product sales to date.」
The company continues to disclose the risk that future performance is difficult to forecast based solely on prior-year performance, given its limited operating history and business characteristics, and the absence of product sales. - FY2020RestatedAnnual report
「We are a company with a limited operating history, having been established in January 2000. We are also a specialized company focused on the so-called drug discovery sector. We plan to generate business revenue and secure profits in the future by launching anticancer drugs we develop, but we have not generated business revenue from product sales to date.」
The company continues to disclose the risk that future performance is difficult to forecast based solely on prior-year performance, given its limited operating history and business characteristics, and the absence of product sales. - FY2019First statedAnnual report
「We are a company with a limited operating history, having been established in January 2000. We are also a specialized company focused on the so-called drug discovery sector. We plan to generate business revenue and secure profits in the future by launching anticancer drugs we develop, but we have not generated business revenue from product sales to date.」
The company discloses, as an organizational and business-foundation risk, that because it has no product sales, unforeseen business problems and changes in the external environment are difficult to predict based solely on prior-year performance.